Navigation Links
Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
Date:11/3/2008

s annual meeting and scientific exposition, in Philadelphia, Pennsylvania, USA on November 4-9, 2008. Dr. Michal Dranitzki Elhalel, principal nephrologist in the study will present on Thursday, November 6, 2008 at 4:45 p.m. at the Clinical Nephrology Conference and Medgenics Senior Scientists will present Medgenics' GMP vector and Toxicity Study in the Poster Session on Saturday, November 8, beginning at 10:00 am, at the Pennsylvania Convention Center.

Commenting on the preliminary results, Dr. Andrew Pearlman, Chief Executive Officer of Medgenics, said:

"While early data from the first two subjects is only a first indicator from this 30 subject study, we are encouraged that this study will show that Medgenics' EPODURE Biopump can be used to safely elevate hemoglobin levels in subjects with chronic kidney disease for three to six months (or more) from a single implant of one or more Biopumps. We look forward to reporting further as the study proceeds but, given the data collected and the apparent lack of an adverse immune response to the technology so far, we are cautiously optimistic that the trial will support the Directors' belief in this breakthrough platform technology."

For further information, contact:

Medgenics, Inc. Phone: +972 4 902 8900

Dr. Andrew L. Pearlman

Grayling Global (Financial PR, UK) Phone: +44 207 255 5406

Jonathan Shillington jonathan.shillington@uk.grayling.com

Alistair Scott

Blomfield Corporate Finance Limited Phone: +44 207 489 4500

(Nominated Adviser)

James Pinner

Alan MacKenzie

SVS Securities plc (Broker) Phone: +44 207 638 5600

Peter Manfield

Ian Callaway

United States contacts:

Grayling Global, Investor Relations Phone: +1 646 284 8472

Leslie Wolf-Creutzfeldt

SOURCE Medgenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MO (PRWEB) July 28, 2014 ... and services that bring the power of genomics to ... inaugural Appistry Pipeline Challenge . , Two ... president of the National Center for Genome Resources, and ... Hospitals and Clinics of Kansas City. Rounding out the ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/28/2014)... The National Model Aviation Museum, located ... pleased to announce that it has been granted full ... United States Air Force. , The certification is the ... this spring with an on-site inspection by Sarah Sessions, ... The National Museum of the United States Air ...
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
(Date:7/25/2014)... A study published online in the International ... novel approach to preventing cervical cancer based on findings ... after removal of a discrete population of cells in ... study that looked at squamocolumnar junction cells, or SCJ ... have been implicated as the origins of cervical cancer. ...
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... of a molecular testing panel developed at UPMC ... initial surgery for patients with thyroid nodules and ... Cancer Institute (UPCI), partner with UPMC CancerCenter., The ... and other diagnostic testing agencies, improved the chances ... 30 percent, according to the study published this ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... of genetic regions known to be implicated in Crohn,s disease, ... research, published today in the journal Nature Genetics , ... development as well as providing surprising new links between the ... disease affects between 1 in 500 and 1 in 1000 ...
... choosing mates. Flowering plant pollination systems are clever ... there are also mechanisms for keeping out unwanted pollen. ... reject such pollen because of the deleterious effects of inbreeding. ... close relatives is rejected if it lands on the female ...
... Two Montana state University researchers are principal editors on ... ways to study carnivores in the wild. "Noninvasive ... June 27 with Robert Long and Paula MacKay as ... Western Transportation Institute. Working with two co-editors ...
Cached Biology News:Complexity of Crohn's disease revealed as 'gene' count tops 30 2Complexity of Crohn's disease revealed as 'gene' count tops 30 3Mate choice in plants 2Mate choice in plants 3
Proteinase K Buffer 3.9 ml...
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Glutathione Agarose Beads 10 ml...
Biology Products: